GlassScriptPhysician profile
Fouad Moursi
NPI 1245752021
$1,869.60
in general payments reported to CMS, 2019-2025
17 companies · $733 in 2025
The $733 reported for 2025 was more than what 89% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $320 · 2023: $334 · 2024: $482 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.14 | 2023-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $142.39 | 2023-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $139.36 | 2023-2025 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $133.98 | 2025 | |
| Phathom Pharmaceuticals, INC. | $130.66 | 2024 | Voquezna |
| Abbvie INC. | $120.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.25 | 2025 | |
| Novartis Pharmaceuticals Corporation | $90.33 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.64 | 2022 | |
| Averitas Pharma INC. | $57.06 | 2025 | Qutenza |
| Lilly USA, LLC | $52.78 | 2022-2023 | Mounjaro |
| Dexcom, INC. | $50.85 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $41.18 | 2024-2025 | Wegovy |
| Phadia US INC. | $21.99 | 2022 | |
| Si-Bone, INC. | $21.87 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.94 | 2025 | Gardasil 9, Capvaxive |
| Medtronic, INC. | $13.57 | 2024 | Venaseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Moursi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.